| SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS |
The
revenue recognized under the MPAR Grant and OUD Grant was as follows:
SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| MPAR | |
$ | 1,164,315 | | |
$ | 1,371,438 | | |
$ | 2,125,313 | | |
$ | 2,691,210 | |
| Total | |
$ | 1,164,315 | | |
$ | 1,371,438 | | |
$ | 2,125,313 | | |
$ | 2,691,210 | |
|
| SCHEDULE OF UNBILLED RECEIVABLE |
Unbilled
receivable from the MPAR Grant consisted of the following:
SCHEDULE
OF UNBILLED RECEIVABLE
| | |
June 30, 2026 | | |
December 31, 2025 | |
| Unbilled receivable - beginning | |
$ | 420,345 | | |
$ | 124,115 | |
| Unbilled receivable - ending | |
$ | 416,811 | | |
$ | 420,345 | |
|
| SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES |
The
following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because
they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price
for the Convertible Notes for the purposes of the weighted average share calculation below):
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Stock options | |
| 93,281 | | |
| 100,675 | | |
| 93,281 | | |
| 71,050 | |
| Warrants | |
| 11,092,740 | | |
| 3,262,893 | | |
| 6,279,475 | | |
| 3,032,161 | |
| Convertible notes | |
| 579 | | |
| 2,290 | | |
| 2,844 | | |
| 4,556 | |
| Consultant shares | |
| 2,175,278 | | |
| 4,600 | | |
| 2,175,278 | | |
| 4,600 | |
| Conversions from preferred shares | |
| 5,390,965 | | |
| - | | |
| 5,390,965 | | |
| - | |
| Total | |
| 18,752,843 | | |
| 3,370,458 | | |
| 13,941,843 | | |
| 3,112,367 | |
|